隨著油價下跌 富時指數(shù)走低

據(jù)路透社7月20日報道，因?qū)σ咔榈膿鷳n加劇，周一能源類股票隨著油價下跌，富時100指數(shù)下跌，。

以大宗商品為主的藍籌股指數(shù)下跌0.9%，英國石油公司(BP Plc)和荷蘭皇家殼牌公司(Royal Dutch Shell Plc)跌幅最大。富時250指數(shù)下跌0.5%，金融、非必需消費品和房地產(chǎn)類股領跌。

歐洲股市本周開局也不樂觀，歐盟領導人仍在就疫情恢復基金的條款進行談判，此前歐盟領導人就該計劃談判了三天。

FXTM市場策略師Hussein Sayed表示："在股市從3月低點大幅上漲后，市場需要另一劑利好消息來維持漲勢，但鑒于未來的諸多不確定性，市場似乎趨于下行。"

在3月份疫情引發(fā)崩盤后，富時100指數(shù)已反彈了約27%，但由于擔心全球經(jīng)濟復蘇慢于預期，自6月份以來，漲幅有所放緩。

最近的一項調(diào)查顯示，近一半的英國大公司認為，企業(yè)要到2021年下半年才能從疫情中恢復過來。

當天晚些時候，所有人都將目光聚焦于阿斯利康公司(AstraZeneca Plc)和牛津大學(Oxford University)開發(fā)的一種疫苗的早期人體試驗數(shù)據(jù)。數(shù)據(jù)公布前，阿斯利康的股價攀升5%，創(chuàng)下歷史新高。

王佳晶 摘譯自 路透社

原文如下：

Oil stocks drag FTSE lower; M&S hit by job cuts report

The FTSE 100 fell on Monday, with energy stocks tracking a decline in oil prices on concerns about the global spike in COVID-19 cases, while Marks and Spencer (MKS.L) slid after a report that the retailer was planning to cut hundreds of jobs.

The commodity-heavy blue-chip index .FTSE was down 0.9%, with BP Plc (BP.L) and Royal Dutch Shell Plc (RDSa.L) among the biggest drags. The mid-cap FTSE 250 .FTMC shed 0.5%, led by financials, consumer discretionary and real-estate stocks.

Stock markets in Europe also kicked off the week on a glum note with EU leaders still negotiating the terms of a coronavirus recovery fund after three days of haggling over the plan.

“Following the (steep rise) from March lows, markets need another dose of positive news to keep the rally going, but given the many uncertainties ahead, the risks seem tilted to the downside,” said Hussein Sayed, market strategist at FXTM.

The FTSE 100 has bounced about 27% following a coronavirus-driven crash in March, but the pace of gains has slowed since June amid fears of a slower-than-expected global economic recovery.

A recent survey showed that nearly half of Britain’s biggest companies think they will take until the second half of 2021 before businesses recover from the pandemic.

Later in the day, all eyes are expected to be on early-stage human trial data on a vaccine being developed by AstraZeneca Plc (AZN.L) and Oxford University. AstraZeneca’s shares climbed 5% to a record high ahead of the data.